With the holiday season in full swing, it’s the perfect opportunity to take a look back at 2017. It’s been a year full of ups and downs, and while there were definitely quite a few low moments, there were certainly quite a few highs. To celebrate the year that was,…
ALS News Today: A Look Back at 2017
Gene editing may be a viable tool to slow disease-causing processes in amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, a mouse study indicates. Published in the journal Science Advances, the study demonstrated that the method delayed disease…
Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM. The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments.
Patients with amyotrophic lateral sclerosis (ALS) experience a gradual loss of the ability to walk, swallow and even breathe, and there’s no cure. It’s incredibly important that patients seek specialized treatment to address the different aspects of the disease. MORE: Find out seven ways to diagnose ALS In…
A group of women in their 60s decided to go full Monty to raise awareness for amyotrophic lateral sclerosis (ALS). The idea came from lifelong friends of Wendy Rauwerdink of Sheboygan, Wisconsin, who had diagnosed with the disease. Her friends became engaged in the fight, always wanting to do more. As…
Two young companies, QurAlis and Kernal Biologics, are winners of the Amgen Golden Tickets for innovative bioscience projects — in this case, work that might lead to better treatments in amyotrophic lateral sclerosis (ALS) and cancer immunotherapy, Amgen and LabCentral announced. QurAlis is developing therapies for three different forms of…
Social Clips
Neurologist Talks About Diagnosing ALS
In this video from the Brattleboro Reformer, learn more about how ALS patients like Andy are diagnosed from a doctor’s point of view. MORE: Andy shares his ALS journey in this touching video Neurologist Dr. Elijah Stommel explains that he sees two newly diagnosed ALS patients each week and that each…
With 2017 quickly coming to a close, I decided to learn a little more about my readers and which of my posts were the most popular. While scrolling through the numbers I identified my most-read posts and the posts that drew the most comments. I learned that ultimately, we…
The Wave Life Sciences therapy WVE-3972-01 reduced markers of the form of ALS that scientists believe stems from a gene mutation, studies show. Researchers said the potential treatment blocked faulty versions of messenger RNA associated with the production of abnormal C9orf72 protein. The RNA is an intermediary between the C9orf72 gene…
MediciNova announced successful top-line results from a Phase 2 clinical trial of MN-166 (ibudilast) as an adjunct therapy to Rilutek (riluzole) in patients with amyotrophic lateral sclerosis (ALS). The treatment was safe and well-tolerated – meeting the trial’s primary endpoint – and was found to be more effective at…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002